Ligand id: 8969

Name: serabelisib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 98.89
Molecular weight 363.13
XLogP 1.65
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
A Phase 2 clinical trial assessing serabelisib (which has variably been known as INK-1117, MLN1117 and TAK-117) with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; NCT02393209) was terminated due to a lack of efficacy of this drug combination. Various Phase 1 and 2 trials with different drug combinations and in different tumour types are ongoing as of October 2018. Click here to link to's full list of serabelisib trials.